Authors : Omolu Ernest Chijioke

Volume/Issue : Volume 9 - 2024, Issue 11 - November

Google Scholar : https://tinyurl.com/ys345ar9

Scribd : https://tinyurl.com/2eekybhd

DOI : https://doi.org/10.38124/ijisrt/IJISRT24NOV674

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Introduction Hypogonadism is a common condition in the general population, affecting males and females. Data on the effects of testosterone replacement therapy on stroke (cerebrovascular accident) and cardiovascular illnesses show conflicting results. The condition can be well managed but the controversy surrounding the use of TRT may cause delay or unwillingness in seeking treatment. The purpose of this narrative review is to ascertain how testosterone replacement medication affects the prevalence of stroke and cardiovascular disease as well as the risk factors causing these diseases.  Measurements: Studies included in this project met the following criteria; males above 18 years, only original peer- reviewed research articles, online publications between 2000 and 2023, text in English. While non-human studies, not full text and abstract only studies were excluded.  Findings: Research on the effects of testosterone replacement therapy on cardiovascular diseases and stroke has produced conflicting results, and the majority of the available data comes from retrospective studies. While many studies found no effect or reduced risk of stroke and cardiovascular diseases following the use of testosterone replacement therapy, a few other studies linked factors such as the route of administration (intramuscular) and period of exposure (within 2 years of treatment) to an increased risk of developing cardiovascular events such as myocardial infarction, heart failure, hypertension, coronary artery diseases and stroke.

Keywords : Testosterone Replacement Therapy, Coronary Artery Disease, Stroke, HRT And Cardiovascular Diseases, Hypogonadism, Testosterone.

References :

1. Ahmed T, Alattar M, Pantalone K, Haque R. Is Testosterone Replacement Safe in Men with Cardiovascular Disease? Cureus. 2020 Mar 19;12(3):e7324. doi: 10.7759/cureus.7324. PMID: 32313765; PMCID: PMC7164696.
2. Belchetz PE, Barth JH, Kaufman JM. Biochemical endocrinology of the hypogonadal male. Ann Clin Biochem 2010;47:503–15. [PubMed] [Google Scholar] [Ref list]
3. Araujo AB,O’Donnell AB, Brambilla DJ, Simpsom WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004 Dec, 89(12):5920-6. Doi: 10.1210/jc.2003-031719.PMID: 15579737.
4. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015. February; 90 2: 224– 51. [PubMed] [Google Scholar] [Ref list]
5. Goodale T, Sadhu A, Petak S, Robbins R. Testosterone and the Heart. Methodist Debakey Cardiovasc J. 2017 Apr-Jun;13(2):68-72. doi: 10.14797/mdcj-13-2-68. PMID: 28740585; PMCID: PMC5512682.
6. Yang Q, Li Z, Li W, Lu L, Wu H, Zhuang Y, Wu K, Sui X. Association of total testosterone, free testosterone, bioavailable testosterone, sex hormone-binding globulin, and hypertension. Medicine (Baltimore). 2019 May;98(20):e15628. doi: 10.1097/MD.0000000000015628. PMID: 31096475; PMCID: PMC6531235.
7. Vigen R, O’Donnell CI, Barón AE, et al. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 2013;310(17):1829–1836. doi:10.1001/jama.2013.280386
8. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med. 2010 Jul 8;363(2):109-22. doi: 10.1056/NEJMoa1000485. Epub 2010 Jun 30. PMID: 20592293; PMCID: PMC3440621.
9. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006 Oct 24;114(17):1829-37. doi: 10.1161/CIRCULATIONAHA.106.649426. Epub 2006 Oct 9. PMID: 17030678.
10. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014 Jan 29;9(1):e85805. doi: 10.1371/journal.pone.0085805. PMID: 24489673; PMCID: PMC3905977.
11. Baillargeon J, Urban RJ, Kuo Y-F, et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Annals of Pharmacotherapy. 2014;48(9):1138-1144. doi:10.1177/1060028014539918
12. Huisman HW, Schutte AE, Van Rooyen JM, Malan NT, Malan L, Schutte R, Kruger A. The influence of testosterone on blood pressure and risk factors for cardiovascular disease in a black South African population. Ethn Dis. 2006 Summer;16(3):693-8. PMID: 16937606.
13. Bu B. Yeap, Zoë Hyde, Osvaldo P. Almeida, Paul E. Norman, S. A. Paul Chubb, Konrad Jamrozik, Leon Flicker, Graeme J. Hankey, Lower Testosterone Levels Predict Incident Stroke and Transient Ischemic Attack in Older Men, The Journal of Clinical Endocrinology & Metabolism, Volume 94, Issue 7, 1 July 2009, Pages 2353–2359, https://doi.org/10.1210/jc.2008-2416
14. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000 Jun;21(11):890-4. doi: 10.1053/euhj.1999.1873. PMID: 10806012.
15. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011 Jun;97(11):870-5. doi: 10.1136/hrt.2010.210757. Epub 2010 Dec 21. PMID: 21177660.
16. Pugh PJ, Channer KS, Parry H, Downes T, Jone TH. Bio-available testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocr Res. 2002 Aug;28(3):161-73. doi: 10.1081/erc-120015055. PMID: 12489566.
17. Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008;31(2):71-9. doi: 10.1159/000119417. Epub 2008 Mar 4. PMID: 18319594.
18. Nettleship J, Jones R, Channer K, Jones T. Testosterone and coronary artery disease. Front Horm Res. 2009;37:91-107. doi: 10.1159/000176047. PMID: 19011291.
19. Malkin CJ, Pugh PJ, West JN, Van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27:57–64. https://doi.org/10.1093/eurheartj/ehi443.
20. Scott JM, Dillon EL, Kinsky M, Chamberlain A, McCammon S, et al. Effects of adjunct testosterone on cardiac morphology and function in advanced cancers: an ancillary analysis of a randomized controlled trial. BMC Cancer. 2019;19:778. [PMC free article] [PubMed] [Google Scholar] [Ref list]
21. Vikan T, Schirmer H, Njolstad I, et al. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type. European Journal of Endocrinology. 2010;162:747–754. [PubMed] [Google Scholar] [Ref list]
22. Gagliano-Jucá, T., Basaria, S. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol 16, 555–574 (2019). https://doi.org/10.1038/s41569-019-0211-4
23. Tan RS, Cook KR, Reilly WG. Myocardial Infarction and Stroke Risk in Young Healthy Men Treated with Injectable Testosterone. Int J Endocrinol. 2015;2015:970750. doi: 10.1155/2015/970750. Epub 2015 Jun 1. PMID: 26124832; PMCID: PMC4466480.
24. Lopes RA, Neves KB, Carneiro FS, Tostes RC. Testosterone and vascular function in aging. Front Physiol. 2012 Apr 10;3:89. doi: 10.3389/fphys.2012.00089. PMID: 22514541; PMCID: PMC3322529.
25. Velho I, Fighera TM, Ziegelmann PK, Spritzer PM. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology. 2017 Sep;5(5):881-888. doi: 10.1111/andr.12382. Epub 2017 Jul 14. PMID: 28709177.
26. Lincoff A. Michael, Bhasin Shalender, Flevaris Panagiotis, Mitchell Lisa M, Basaria Shehzad, Boden William E, Cunningham Glenn R, Granger Christopher B,  Khera Mohit, Thompson Ian M, Wang Qiuqing, Wolski, Kathy, Davey Deborah, Kalahasti Vidyasagar, Khan Nader, Miller Michael G, Snabes Michael C, Chan Anna, Dubcenco Elena, Li Xue, Yi Tingting, Huang Bidan, Pencina Karol, M Travison, Thomas G, Nissen Steven E. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine 2023/10/19; 107: 117-2. doi: 10.1056/NEJMoa2215025. JOUR 2023 New England Journal of Medicine: 2023/07/13; 0028-4793 https://doi.org/10.1056/NEJMoa2215025
27. Keating N. L., O’Malley A. J., Smith M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448–4456. 10.1200/JCO.2006.06.2497 [PubMed] [CrossRef] [Google Scholar] [Ref list]
28. Mathews L, Subramanya V, Zhao D, Ouyang P, Vaidya D, Guallar E, Yeboah J, Herrington D, Hays AG, Budoff MJ, Michos ED. Endogenous Sex Hormones and Endothelial Function in Postmenopausal Women and Men: The Multi-Ethnic Study of Atherosclerosis. J Womens Health (Larchmt). 2019 Jul;28(7):900-909. doi: 10.1089/jwh.2018.7441. Epub 2019 Jun 6. PMID: 31170017; PMCID: PMC6645200.
29. von Mering GO, Arant CB, Wessel TR, et al.. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: Results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:722–725 [PubMed] [Google Scholar] [Ref list]
30. Zhao D, Guallar E, Ouyang P, Subramanya V, Vaidya D, Ndumele CE, Lima JA, Allison MA, Shah SJ, Bertoni AG, Budoff MJ, Post WS, Michos ED. Endogenous Sex Hormones and Incident Cardiovascular Disease in Post-Menopausal Women. J Am Coll Cardiol. 2018 Jun 5;71(22):2555-2566. doi: 10.1016/j.jacc.2018.01.083. PMID: 29852978; PMCID: PMC5986086.
31. Martinez-Quintana E, Saiz-Udaeta B, Marrero-Negrin N, Lopez-Mérida X, Rodriguez-Gonzalez F, Nieto-Lago V. Androgenic anabolic steroid, cocaine and amphetamine abuse and adverse cardiovascular effects. Int J Endocrinol Metab. 2013 Oct 1;11(4):e8755. doi: 10.5812/ijem.8755. PMID: 24719633; PMCID: PMC3968994.
32. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008 Jan;93(1):68-75. doi: 10.1210/jc.2007-1792. Epub 2007 Oct 2. PMID: 17911176; PMCID: PMC2190742.
33. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec;116(23):2694-2701. DOI: 10.1161/circulationaha.107.719005. PMID: 18040028.
34. Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013 Jul;75(3):282-288. DOI: 10.1016/j.maturitas.2013.04.012. PMID: 23706278.
35. Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, Ljunggren O, Vandenput L, Mellström D, Tivesten A. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011 Oct 11;58(16):1674-81. doi: 10.1016/j.jacc.2011.07.019. PMID: 21982312.
36. Nguyen CP, Hirsch MS, Moeny D, Kaul S, Mohamoud M, Joffe HV. Testosterone and "Age-Related Hypogonadism"--FDA Concerns. N Engl J Med. 2015 Aug 20;373(8):689-91. doi: 10.1056/NEJMp1506632. PMID: 26287846; PMCID: PMC8905399.
37. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013 Oct 21;199(8):548-51. doi: 10.5694/mja13.10111. PMID: 24138381.
38. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS; Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016 Feb 18;374(7):611-24. doi: 10.1056/NEJMoa1506119. PMID: 26886521; PMCID: PMC5209754.
39. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. The Journal of Clinical Endocrinology and Metabolism. 2012 Jun;97(6):2050-2058. DOI: 10.1210/jc.2011-2591. PMID: 22496507.
40. Shores MM, Arnold AM, Biggs ML, Longstreth WT Jr, Smith NL, Kizer JR, Cappola AR, Hirsch CH, Marck BT, Matsumoto AM. Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study. Clin Endocrinol (Oxf). 2014 Nov;81(5):746-53. doi: 10.1111/cen.12452. Epub 2014 May 5. PMID: 24645738; PMCID: PMC4169352.
41. Srinath R, Gottesman RF, Hill Golden S, Carson KA, Dobs A. Association Between Endogenous Testosterone and Cerebrovascular Disease in the ARIC Study (Atherosclerosis Risk in Communities). Stroke. 2016 Nov;47(11):2682-2688. doi: 10.1161/STROKEAHA.116.014088. Epub 2016 Oct 11. PMID: 27729576.
42. Magnani JW, Moser CB, Murabito JM, Sullivan LM, Wang N, Ellinor PT, Vasan RS, Benjamin EJ, Coviello AD. Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2014 Apr;7(2):307-12. doi: 10.1161/CIRCEP.113.001322. Epub 2014 Mar 8. PMID: 24610804; PMCID: PMC4035016.
43. Rosenberg MA, Shores MM, Matsumoto AM, Bůžková P, Lange LA, Kronmal RA, Heckbert SR, Mukamal KJ. Serum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study. Clin Cardiol. 2018 Jun;41(6):830-836. doi: 10.1002/clc.22965. Epub 2018 Jun 8. PMID: 29671886; PMCID: PMC6013387.
44. Zeller T, Schnabel RB, Appelbaum S, Ojeda F, Berisha F, Schulte-Steinberg B, Brueckmann BE, Kuulasmaa K, Jousilahti P, Blankenberg S, Palosaari T, Salomaa V, Karakas M. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women - results from the FINRISK study. Eur J Prev Cardiol. 2018 Jul;25(11):1133-1139. doi: 10.1177/2047487318778346. Epub 2018 May 29. PMID: 29808758.
45. Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA, Yeap BB. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab. 2012 Jan;97(1):179-89. doi: 10.1210/jc.2011-1617. Epub 2011 Oct 19. PMID: 22013106.
46. Chan YX, Knuiman MW, Hung J, Divitini ML, Beilby JP, Handelsman DJ, Beilin J, McQuillan B, Yeap BB. Neutral associations of testosterone, dihydrotestosterone and estradiol with fatal and non-fatal cardiovascular events, and mortality in men aged 17-97 years. Clin Endocrinol (Oxf). 2016 Oct;85(4):575-82. doi: 10.1111/cen.13089. Epub 2016 May 8. PMID: 27106765.
47. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011 Dec;60(6):1244-50. doi: 10.1016/j.eururo.2011.08.041. Epub 2011 Aug 27. PMID: 21908097.
48. Martín-Merino E, Johansson S, Morris T, García Rodríguez LA. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf. 2011 Nov 1;34(11):1061-77. doi: 10.2165/11594540-000000000-00000. PMID: 21981434.
49. Maggi M, Wu FC, Jones TH, Jackson G, Behre HM, Hackett G, Martin-Morales A, Balercia G, Dobs AS, Arver ST, Maggio M, Cunningham GR, Isidori AM, Quinton R, Wheaton OA, Siami FS, Rosen RC; RHYME Investigators. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). Int J Clin Pract. 2016 Oct;70(10):843-852. doi: 10.1111/ijcp.12876. PMID: 27774779.
50. Arnlöv J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D'Agostino RB Sr, Bhasin S, Vasan RS. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1;145(3):176-84. doi: 10.7326/0003-4819-145-3-200608010-00005. PMID: 16880459.
51. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism. 1997 Jun;82(6):1661-1667. DOI: 10.1210/jcem.82.6.3988. PMID: 9177359.